Eli Lilly (LLY)
(Delayed Data from NYSE)
$762.66 USD
+8.49 (1.13%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $762.65 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Eli Lilly and Company falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2,928 | 2,212 | 3,909 | 3,681 | 2,439 |
Receivables | 11,336 | 8,559 | 8,127 | 6,929 | 5,542 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 5,773 | 4,310 | 3,886 | 3,980 | 3,191 |
Other Current Assets | 5,690 | 2,954 | 2,531 | 2,872 | 2,539 |
Total Current Assets | 25,727 | 18,035 | 18,452 | 17,462 | 13,710 |
Net Property & Equipment | 12,914 | 10,144 | 8,985 | 8,682 | 7,873 |
Investments & Advances | 3,052 | 2,902 | 3,213 | 2,967 | 1,962 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 5,477 | 2,793 | 2,489 | 2,830 | 2,573 |
Intangibles | 11,846 | 11,280 | 11,584 | 11,217 | 10,297 |
Deposits & Other Assets | 4,990 | 4,337 | 4,083 | 3,475 | 2,339 |
Total Assets | 64,006 | 49,490 | 48,806 | 46,633 | 39,286 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 6,905 | 1,501 | 0 | 9 | 1,499 |
Accounts Payable | 2,599 | 1,931 | 1,671 | 1,607 | 1,405 |
Current Portion Long-Term Debt | 0 | 0 | 1,538 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 475 | 127 | 495 | 161 |
Other Current Liabilities | 17,790 | 13,231 | 11,717 | 10,371 | 8,710 |
Total Current Liabilities | 27,293 | 17,138 | 15,053 | 12,482 | 11,775 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 87 | 1,734 | 2,100 | 2,188 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 18,321 | 14,738 | 15,346 | 16,587 | 13,818 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 7,529 | 6,751 | 7,518 | 9,640 | 8,320 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 53,143 | 38,714 | 39,651 | 40,808 | 36,587 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 594 | 594 | 596 | 598 | 599 |
Capital Surplus | 7,250 | 6,921 | 6,833 | 6,779 | 6,685 |
Retained Earnings | 10,312 | 10,043 | 8,959 | 7,830 | 4,920 |
Other Equity | -7,248 | -6,732 | -7,181 | -9,326 | -9,445 |
Treasury Stock | 44 | 51 | 53 | 56 | 61 |
Total Shareholder's Equity | 10,864 | 10,775 | 9,155 | 5,825 | 2,699 |
Total Liabilities & Shareholder's Equity | 64,006 | 49,490 | 48,806 | 46,633 | 39,286 |
Total Common Equity | 10,864 | 10,775 | 9,155 | 5,825 | 2,699 |
Shares Outstanding | 949.30 | 950.10 | 956.50 | 956.50 | 960.10 |
Book Value Per Share | 11.44 | 11.34 | 9.57 | 6.09 | 2.81 |
Fiscal Year End for Eli Lilly and Company falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2,928 | 2,494 | 2,829 | 3,669 | 2,212 |
Receivables | 11,336 | 10,364 | 9,171 | 9,022 | 8,559 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 5,773 | 4,901 | 4,799 | 4,545 | 4,310 |
Other Current Assets | 5,690 | 5,248 | 4,532 | 3,575 | 2,954 |
Total Current Assets | 25,727 | 23,007 | 21,332 | 20,811 | 18,035 |
Net Property & Equipment | 12,914 | 11,863 | 11,277 | 10,546 | 10,144 |
Investments & Advances | 3,052 | 2,692 | 2,745 | 2,750 | 2,902 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 5,477 | 4,575 | 3,806 | 3,407 | 2,793 |
Intangibles | 11,846 | 10,867 | 10,982 | 11,160 | 11,280 |
Deposits & Other Assets | 4,990 | 4,912 | 4,672 | 4,488 | 4,337 |
Total Assets | 64,006 | 57,916 | 54,814 | 53,163 | 49,490 |
Liabilities & Shareholders Equity | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 |
---|---|---|---|---|---|
Notes Payable | 6,905 | 2,245 | 662 | 3 | 1,501 |
Accounts Payable | 2,599 | 2,435 | 2,474 | 2,016 | 1,931 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 1,978 | 1,234 | 1,528 | 475 |
Other Current Liabilities | 17,790 | 15,341 | 14,545 | 12,463 | 13,231 |
Total Current Liabilities | 27,293 | 21,998 | 18,915 | 16,010 | 17,138 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 87 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 18,321 | 17,924 | 18,158 | 18,881 | 14,738 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 7,529 | 6,591 | 6,978 | 6,751 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 53,143 | 46,608 | 43,665 | 41,868 | 38,714 |
Shareholders Equity | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 594 | 594 | 594 | 594 | 594 |
Capital Surplus | 7,250 | 7,160 | 6,949 | 6,793 | 6,921 |
Retained Earnings | 10,312 | 10,310 | 10,369 | 10,639 | 10,043 |
Other Equity | -7,248 | -6,711 | -6,716 | -6,686 | -6,732 |
Treasury Stock | 44 | 45 | 45 | 45 | 51 |
Total Shareholder's Equity | 10,864 | 11,307 | 11,149 | 11,295 | 10,775 |
Total Liabilities & Shareholder's Equity | 64,006 | 57,916 | 54,814 | 53,163 | 49,490 |
Total Common Equity | 10,864 | 11,307 | 11,149 | 11,295 | 10,775 |
Shares Outstanding | 949.30 | 949.30 | 949.20 | 949.20 | 950.10 |
Book Value Per Share | 11.44 | 11.91 | 11.75 | 11.90 | 11.34 |